$ALHC
Alignment Healthcare, Inc.

2023 Q4 Form 10-Q Financial Statement

#000095017023058207 Filed on November 02, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3 2022 Q3
Revenue $465.4M $456.7M $360.3M
YoY Change 28.63% 26.74% 22.79%
Cost Of Revenue $417.8M $397.9M $312.9M
YoY Change 28.15% 27.19% 23.17%
Gross Profit $47.63M $58.80M $47.50M
YoY Change 33.0% 23.79% 20.32%
Gross Profit Margin 10.23% 12.87% 13.18%
Selling, General & Admin $83.74M $83.09M $76.45M
YoY Change 0.61% 8.68% -0.51%
% of Gross Profit 175.83% 141.31% 160.96%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $5.861M $5.497M $4.456M
YoY Change 23.36% 23.36% 9.22%
% of Gross Profit 12.31% 9.35% 9.38%
Operating Expenses $89.54M $486.5M $393.8M
YoY Change 1.85% 23.54% 17.57%
Operating Profit -$41.91M -$29.76M -$33.41M
YoY Change -19.56% -10.94% -19.4%
Interest Expense -$5.484M $5.466M $4.605M
YoY Change 14.42% 18.7% 4.33%
% of Operating Profit
Other Income/Expense, Net $142.0K -$5.321M -$6.670M
YoY Change 86.84% -20.22% 52.77%
Pretax Income -$47.26M -$35.08M -$40.08M
YoY Change -16.84% -12.48% -12.52%
Income Tax -$24.00K $0.00 $167.0K
% Of Pretax Income
Net Earnings -$47.21M -$35.05M -$40.25M
YoY Change -17.04% -12.92% -12.16%
Net Earnings / Revenue -10.14% -7.67% -11.17%
Basic Earnings Per Share -$0.19 -$0.22
Diluted Earnings Per Share -$0.25 -$0.19 -$0.22
COMMON SHARES
Basic Shares Outstanding 189.1M 188.4M 187.3M
Diluted Shares Outstanding 188.7M 187.3M

Balance Sheet

Concept 2023 Q4 2023 Q3 2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $318.8M $515.6M $567.4M
YoY Change -22.15% -9.14% 13.38%
Cash & Equivalents $202.9M $391.6M $567.4M
Short-Term Investments $115.9M $123.9M
Other Short-Term Assets $44.97M $45.90M $36.49M
YoY Change 6.8% 25.78% 24.82%
Inventory
Prepaid Expenses
Receivables $119.7M $105.5M $88.22M
Other Receivables $119.7M $105.6M $0.00
Total Short-Term Assets $483.5M $667.0M $692.2M
YoY Change -11.2% -3.64% 19.88%
LONG-TERM ASSETS
Property, Plant & Equipment $51.90M $47.16M $35.58M
YoY Change 39.64% 32.56% 12.92%
Goodwill $34.83M $34.83M $32.04M
YoY Change 0.05% 8.68% 9.35%
Intangibles $5.252M
YoY Change -4.13%
Long-Term Investments
YoY Change
Other Assets $6.405M $6.082M $6.104M
YoY Change 6.13% -0.36% 34.3%
Total Long-Term Assets $108.3M $103.8M $85.38M
YoY Change 21.3% 21.59% 7.35%
TOTAL ASSETS
Total Short-Term Assets $483.5M $667.0M $692.2M
Total Long-Term Assets $108.3M $103.8M $85.38M
Total Assets $591.9M $770.8M $777.5M
YoY Change -6.62% -0.87% 18.36%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $228.9M $228.8M $171.4M
YoY Change 13.08% 33.49% 33.1%
Accrued Expenses $34.11M $35.10M $31.41M
YoY Change 23.87% 11.74% 5.37%
Deferred Revenue $146.3M $116.8M
YoY Change 25.33%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00 $0.00
YoY Change
Total Short-Term Liabilities $263.0M $410.3M $340.3M
YoY Change 14.38% 20.58% 94.28%
LONG-TERM LIABILITIES
Long-Term Debt $161.8M $161.6M $160.7M
YoY Change 0.57% 0.57% 7.86%
Other Long-Term Liabilities $8.974M $9.300M $4.458M
YoY Change 142.67% 108.61% -42.43%
Total Long-Term Liabilities $161.8M $161.6M $160.7M
YoY Change 0.57% 0.57% 7.86%
TOTAL LIABILITIES
Total Short-Term Liabilities $263.0M $410.3M $340.3M
Total Long-Term Liabilities $161.8M $161.6M $160.7M
Total Liabilities $433.8M $581.2M $505.4M
YoY Change 9.95% 15.0% 52.3%
SHAREHOLDERS EQUITY
Retained Earnings -$880.3M -$833.0M -$675.3M
YoY Change 20.21% 23.35% 28.14%
Common Stock $189.0K $189.0K $187.0K
YoY Change 1.07% 1.07% -0.53%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $156.9M $188.5M $272.1M
YoY Change
Total Liabilities & Shareholders Equity $591.9M $770.8M $777.5M
YoY Change -6.62% -0.87% 18.36%

Cashflow Statement

Concept 2023 Q4 2023 Q3 2022 Q3
OPERATING ACTIVITIES
Net Income -$47.21M -$35.05M -$40.25M
YoY Change -17.04% -12.92% -12.16%
Depreciation, Depletion And Amortization $5.861M $5.497M $4.456M
YoY Change 23.36% 23.36% 9.22%
Cash From Operating Activities -$187.5M $6.000M $105.1M
YoY Change 25.59% -94.29% 714.0%
INVESTING ACTIVITIES
Capital Expenditures $10.60M $9.600M -$6.548M
YoY Change 64.12% -246.61% 10.11%
Acquisitions
YoY Change
Other Investing Activities $9.579M $0.00 -$1.580M
YoY Change -680.55% -100.0% 50.48%
Cash From Investing Activities -$1.018M -$9.600M -$8.128M
YoY Change -87.44% 18.11% 16.16%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 45.00K 0.000 17.22M
YoY Change -108.54% -100.0%
NET CHANGE
Cash From Operating Activities -187.5M 6.000M 105.1M
Cash From Investing Activities -1.018M -9.600M -8.128M
Cash From Financing Activities 45.00K 0.000 17.22M
Net Change In Cash -188.4M -3.600M 114.2M
YoY Change 19.34% -103.15% 1830.23%
FREE CASH FLOW
Cash From Operating Activities -$187.5M $6.000M $105.1M
Capital Expenditures $10.60M $9.600M -$6.548M
Free Cash Flow -$198.1M -$3.600M $111.7M
YoY Change 27.19% -103.22% 492.06%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001832466
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q3 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2023#FinancialServiceMember
CY2022Q3 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2023#FinancialServiceMember
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2023#FinancialServiceMember
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2023#FinancialServiceMember
us-gaap Acquired Finite Lived Intangible Assets Weighted Average Useful Life
AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
CY2022 us-gaap Acquired Finite Lived Intangible Assets Weighted Average Useful Life
AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-40295
dei Entity Registrant Name
EntityRegistrantName
ALIGNMENT HEALTHCARE, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-5596242
dei Entity Address Address Line1
EntityAddressAddressLine1
1100 W. Town and Country Road
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 1600
dei Entity Address City Or Town
EntityAddressCityOrTown
Orange
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92868
dei City Area Code
CityAreaCode
844
dei Local Phone Number
LocalPhoneNumber
310-2247
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
ALHC
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
189099787
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
391643000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
409549000
CY2023Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
91000
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0
CY2023Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
105523000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
92890000
CY2023Q3 us-gaap Short Term Investments
ShortTermInvestments
123926000
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
0
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
45878000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
42107000
CY2023Q3 us-gaap Assets Current
AssetsCurrent
666970000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
544546000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
47162000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
37169000
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
10472000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5825000
CY2023Q3 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
40106000
CY2022Q4 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
40288000
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
6082000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
6035000
CY2023Q3 us-gaap Assets
Assets
770792000
CY2022Q4 us-gaap Assets
Assets
633863000
CY2023Q3 alhc Medical Expenses Payable Current
MedicalExpensesPayableCurrent
203435000
CY2022Q4 alhc Medical Expenses Payable Current
MedicalExpensesPayableCurrent
170135000
CY2023Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
25356000
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
31980000
CY2023Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
146342000
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
308000
CY2023Q3 alhc Accrued Compensation
AccruedCompensation
35141000
CY2022Q4 alhc Accrued Compensation
AccruedCompensation
27538000
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
410274000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
229961000
CY2023Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
161595000
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
160902000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
9318000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3698000
CY2023Q3 us-gaap Liabilities
Liabilities
581187000
CY2022Q4 us-gaap Liabilities
Liabilities
394561000
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000000
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
188911520
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
188911520
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
187280015
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
187280015
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
189000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
187000
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1021363000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
970180000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-833049000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-732241000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
188503000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
238126000
CY2023Q3 us-gaap Minority Interest
MinorityInterest
1102000
CY2022Q4 us-gaap Minority Interest
MinorityInterest
1176000
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
189605000
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
239302000
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
770792000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
633863000
CY2023Q3 us-gaap Premiums Earned Net
PremiumsEarnedNet
450235000
CY2022Q3 us-gaap Premiums Earned Net
PremiumsEarnedNet
359978000
us-gaap Premiums Earned Net
PremiumsEarnedNet
1341924000
us-gaap Premiums Earned Net
PremiumsEarnedNet
1071450000
CY2023Q3 us-gaap Revenue Not From Contract With Customer
RevenueNotFromContractWithCustomer
6474000
CY2022Q3 us-gaap Revenue Not From Contract With Customer
RevenueNotFromContractWithCustomer
370000
us-gaap Revenue Not From Contract With Customer
RevenueNotFromContractWithCustomer
16319000
us-gaap Revenue Not From Contract With Customer
RevenueNotFromContractWithCustomer
898000
CY2023Q3 us-gaap Revenues
Revenues
456709000
CY2022Q3 us-gaap Revenues
Revenues
360348000
us-gaap Revenues
Revenues
1358243000
us-gaap Revenues
Revenues
1072348000
CY2023Q3 alhc Medical Expenses
MedicalExpenses
397879000
CY2022Q3 alhc Medical Expenses
MedicalExpenses
312850000
alhc Medical Expenses
MedicalExpenses
1204838000
alhc Medical Expenses
MedicalExpenses
923877000
CY2023Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
83089000
CY2022Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
76452000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
223696000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
212418000
CY2023Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
5497000
CY2022Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
4456000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
15613000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
12586000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
486465000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
393758000
us-gaap Operating Expenses
OperatingExpenses
1444147000
us-gaap Operating Expenses
OperatingExpenses
1148881000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-29756000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-33410000
us-gaap Operating Income Loss
OperatingIncomeLoss
-85904000
us-gaap Operating Income Loss
OperatingIncomeLoss
-76533000
CY2023Q3 us-gaap Interest Expense
InterestExpense
5466000
CY2022Q3 us-gaap Interest Expense
InterestExpense
4605000
us-gaap Interest Expense
InterestExpense
15747000
us-gaap Interest Expense
InterestExpense
13496000
CY2023Q3 alhc Other Non Operating Expense Income
OtherNonOperatingExpenseIncome
-145000
CY2022Q3 alhc Other Non Operating Expense Income
OtherNonOperatingExpenseIncome
-131000
alhc Other Non Operating Expense Income
OtherNonOperatingExpenseIncome
-711000
alhc Other Non Operating Expense Income
OtherNonOperatingExpenseIncome
252000
CY2023Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
CY2022Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-2196000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-2196000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-5321000
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-6670000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-15036000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-15944000
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-35077000
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-40080000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-100940000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-92477000
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
167000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
167000
CY2023Q3 us-gaap Profit Loss
ProfitLoss
-35077000
CY2022Q3 us-gaap Profit Loss
ProfitLoss
-40247000
us-gaap Profit Loss
ProfitLoss
-100942000
us-gaap Profit Loss
ProfitLoss
-92644000
CY2023Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-30000
CY2022Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
0
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-134000
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
0
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-35047000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-40247000
us-gaap Net Income Loss
NetIncomeLoss
-100808000
us-gaap Net Income Loss
NetIncomeLoss
-92644000
CY2023Q3 alhc Weighted Average Number Of Shares Outstanding Net Of Restricted Shares Of Common Stock Basic
WeightedAverageNumberOfSharesOutstandingNetOfRestrictedSharesOfCommonStockBasic
187328318
CY2023Q3 alhc Weighted Average Number Of Shares Outstanding Net Of Restricted Shares Of Common Stock Diluted
WeightedAverageNumberOfSharesOutstandingNetOfRestrictedSharesOfCommonStockDiluted
187328318
CY2022Q3 alhc Weighted Average Number Of Shares Outstanding Net Of Restricted Shares Of Common Stock Basic
WeightedAverageNumberOfSharesOutstandingNetOfRestrictedSharesOfCommonStockBasic
182123363
CY2022Q3 alhc Weighted Average Number Of Shares Outstanding Net Of Restricted Shares Of Common Stock Diluted
WeightedAverageNumberOfSharesOutstandingNetOfRestrictedSharesOfCommonStockDiluted
182123363
alhc Weighted Average Number Of Shares Outstanding Net Of Restricted Shares Of Common Stock Basic
WeightedAverageNumberOfSharesOutstandingNetOfRestrictedSharesOfCommonStockBasic
185493345
alhc Weighted Average Number Of Shares Outstanding Net Of Restricted Shares Of Common Stock Diluted
WeightedAverageNumberOfSharesOutstandingNetOfRestrictedSharesOfCommonStockDiluted
185493345
alhc Weighted Average Number Of Shares Outstanding Net Of Restricted Shares Of Common Stock Basic
WeightedAverageNumberOfSharesOutstandingNetOfRestrictedSharesOfCommonStockBasic
180765300
alhc Weighted Average Number Of Shares Outstanding Net Of Restricted Shares Of Common Stock Diluted
WeightedAverageNumberOfSharesOutstandingNetOfRestrictedSharesOfCommonStockDiluted
180765300
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.19
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.19
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.22
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.22
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.54
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.54
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.51
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.51
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
211112000
CY2023Q3 us-gaap Profit Loss
ProfitLoss
-35077000
CY2023Q3 alhc Issuance Of Common Stock Upon Vesting Of Restricted Stock Units Values
IssuanceOfCommonStockUponVestingOfRestrictedStockUnitsValues
1000
CY2023Q3 us-gaap Stock Issued During Period Value Share Based Compensation Forfeited
StockIssuedDuringPeriodValueShareBasedCompensationForfeited
0
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
13569000
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
189605000
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
293704000
CY2022Q3 us-gaap Profit Loss
ProfitLoss
-40247000
CY2022Q3 us-gaap Stock Issued During Period Value Share Based Compensation Forfeited
StockIssuedDuringPeriodValueShareBasedCompensationForfeited
0
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
18687000
CY2022Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
272144000
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
239302000
us-gaap Profit Loss
ProfitLoss
-100942000
alhc Issuance Of Common Stock Upon Vesting Of Restricted Stock Units Values
IssuanceOfCommonStockUponVestingOfRestrictedStockUnitsValues
2000
us-gaap Stock Issued During Period Value Share Based Compensation Forfeited
StockIssuedDuringPeriodValueShareBasedCompensationForfeited
0
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
51183000
us-gaap Minority Interest Decrease From Redemptions
MinorityInterestDecreaseFromRedemptions
-60000
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
189605000
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
306055000
us-gaap Profit Loss
ProfitLoss
-92644000
us-gaap Stock Issued During Period Value Share Based Compensation Forfeited
StockIssuedDuringPeriodValueShareBasedCompensationForfeited
0
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
58833000
us-gaap Minority Interest Decrease From Redemptions
MinorityInterestDecreaseFromRedemptions
100000
CY2022Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
272144000
us-gaap Profit Loss
ProfitLoss
-100942000
us-gaap Profit Loss
ProfitLoss
-92644000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
91000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
150000
alhc Gain Loss On Sublease
GainLossOnSublease
289000
alhc Gain Loss On Sublease
GainLossOnSublease
-510000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
15807000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
12735000
us-gaap Investment Income Amortization Of Discount
InvestmentIncomeAmortizationOfDiscount
3349000
us-gaap Investment Income Amortization Of Discount
InvestmentIncomeAmortizationOfDiscount
8000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
1037000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
1616000
us-gaap Paid In Kind Interest
PaidInKindInterest
0
us-gaap Paid In Kind Interest
PaidInKindInterest
2943000
us-gaap Share Based Compensation
ShareBasedCompensation
51183000
us-gaap Share Based Compensation
ShareBasedCompensation
58833000
us-gaap Operating Lease Cost
OperatingLeaseCost
1653000
us-gaap Operating Lease Cost
OperatingLeaseCost
2151000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-2196000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
12724000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
29840000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3771000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
8742000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
119000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
137000
alhc Increase Decrease In Medical Expenses Payable
IncreaseDecreaseInMedicalExpensesPayable
33299000
alhc Increase Decrease In Medical Expenses Payable
IncreaseDecreaseInMedicalExpensesPayable
45509000
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-4613000
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
2030000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
146034000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
116298000
alhc Increase Decrease In Accrued Compensation
IncreaseDecreaseInAccruedCompensation
7604000
alhc Increase Decrease In Accrued Compensation
IncreaseDecreaseInAccruedCompensation
7484000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-2622000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-3126000
alhc Increase Decrease In Debt Instrument Payment In Kind Interest On Principal Balance
IncreaseDecreaseInDebtInstrumentPaymentInKindInterestOnPrincipalBalance
0
alhc Increase Decrease In Debt Instrument Payment In Kind Interest On Principal Balance
IncreaseDecreaseInDebtInstrumentPaymentInKindInterestOnPrincipalBalance
-14122000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
128279000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
103836000
us-gaap Payments To Acquire Assets Investing Activities
PaymentsToAcquireAssetsInvestingActivities
0
us-gaap Payments To Acquire Assets Investing Activities
PaymentsToAcquireAssetsInvestingActivities
2393000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
281582000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
2825000
us-gaap Proceeds From Maturities Prepayments And Calls Of Longterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfLongtermInvestments
160735000
us-gaap Proceeds From Maturities Prepayments And Calls Of Longterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfLongtermInvestments
2425000
alhc Proceeds From Acquisition Of Property And Equipment
ProceedsFromAcquisitionOfPropertyAndEquipment
-25398000
alhc Proceeds From Acquisition Of Property And Equipment
ProceedsFromAcquisitionOfPropertyAndEquipment
-17317000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-146245000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-20110000
us-gaap Payments To Minority Shareholders
PaymentsToMinorityShareholders
0
us-gaap Payments To Minority Shareholders
PaymentsToMinorityShareholders
100000
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
0
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
165000000
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
0
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
4601000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
0
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
143179000
us-gaap Proceeds From Minority Shareholders
ProceedsFromMinorityShareholders
60000
us-gaap Proceeds From Minority Shareholders
ProceedsFromMinorityShareholders
0
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
60000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
17120000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-17906000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
100846000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
411299000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
468350000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
393393000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
569196000
us-gaap Interest Paid Net
InterestPaidNet
13943000
us-gaap Interest Paid Net
InterestPaidNet
22447000
alhc Acquisition Of Property In Accounts Payable
AcquisitionOfPropertyInAccountsPayable
117000
alhc Acquisition Of Property In Accounts Payable
AcquisitionOfPropertyInAccountsPayable
290000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
375000
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
391643000
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
567446000
CY2023Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
1750000
CY2022Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
1750000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
393393000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
569196000
alhc Number Of Consolidated Variable Interest Entities
NumberOfConsolidatedVariableInterestEntities
3
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:0;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of the condensed consolidated financial statements requires management to make estimates and judgments that affect the amounts reported in the condensed consolidated financial statements. Our significant estimates include, but are not limited to, the determination of medical expenses payable; the impact of risk adjustment provisions related to our Medicare contracts; collectability of receivables; valuation of related impairment recognition of long-lived assets, including goodwill and intangible assets; equity-based compensation expense; and contingent liabilities. Estimates and judgments are based upon historical information and on various other assumptions that are believed to be reasonable under the circumstances. Actual results could differ materially from those estimates and the impact of any change in estimates is included in earnings in the period in which the estimate is adjusted.</span></p>
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
450235000
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
359978000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1341924000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1071450000
CY2023Q3 alhc Interest Income
InterestIncome
5523000
alhc Interest Income
InterestIncome
13967000
CY2022Q3 alhc Interest Income
InterestIncome
29000
alhc Interest Income
InterestIncome
37000
CY2023Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
146342000
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
308000
alhc Schedule Of Property And Equipment Estimated Useful Lives Table Textblock
ScheduleOfPropertyAndEquipmentEstimatedUsefulLivesTableTextblock
<p style="text-indent:0;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Depreciation expense is computed using the straight-line method generally based on the following estimated useful lives:</span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:72.206%;"></td> <td style="width:1.64%;"></td> <td style="width:26.155%;"></td> </tr> <tr style="height:8pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Description</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">Estimated Service Lives (years)</span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Computer and equipment</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5</span></span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Office equipment and furniture</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5</span></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">-</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7</span></span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Software</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3</span></span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">-</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5</span></span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Leasehold improvements</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">15 (or lease term, if shorter)</span></span></p></td> </tr> </table>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk</span></p><p style="text-indent:0;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash deposits and restricted investments with financial institutions. Accounts at each financial institution are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to certain limits. At September 30, 2023 and December 31, 2022, the</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">re was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">390,047</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">408,047</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, res</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">pectively, in excess of FDIC-insured limits.</span></p>
us-gaap Federal Deposit Insurance Corporation Premium Expense
FederalDepositInsuranceCorporationPremiumExpense
390047000
CY2022 us-gaap Federal Deposit Insurance Corporation Premium Expense
FederalDepositInsuranceCorporationPremiumExpense
408047000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Requisite Service Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
P4Y
CY2022Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
0
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
0
CY2023Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-30000
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-134000
CY2023Q3 us-gaap Profit Loss
ProfitLoss
-35077000
CY2022Q3 us-gaap Profit Loss
ProfitLoss
-40247000
us-gaap Profit Loss
ProfitLoss
-100942000
us-gaap Profit Loss
ProfitLoss
-92644000
CY2023Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-30000
CY2022Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
0
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-134000
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
0
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-35047000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-40247000
us-gaap Net Income Loss
NetIncomeLoss
-100808000
us-gaap Net Income Loss
NetIncomeLoss
-92644000
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
188657282
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
188657282
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
187267619
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
187267619
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
188241025
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
188241025
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
187216118
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
187216118
CY2023Q3 us-gaap Weighted Average Number Of Shares Restricted Stock
WeightedAverageNumberOfSharesRestrictedStock
1328964
CY2022Q3 us-gaap Weighted Average Number Of Shares Restricted Stock
WeightedAverageNumberOfSharesRestrictedStock
5144256
us-gaap Weighted Average Number Of Shares Restricted Stock
WeightedAverageNumberOfSharesRestrictedStock
2747680
us-gaap Weighted Average Number Of Shares Restricted Stock
WeightedAverageNumberOfSharesRestrictedStock
6450818
CY2023Q3 alhc Weighted Average Number Of Shares Outstanding Net Of Restricted Shares Of Common Stock Diluted
WeightedAverageNumberOfSharesOutstandingNetOfRestrictedSharesOfCommonStockDiluted
187328318
CY2023Q3 alhc Weighted Average Number Of Shares Outstanding Net Of Restricted Shares Of Common Stock Basic
WeightedAverageNumberOfSharesOutstandingNetOfRestrictedSharesOfCommonStockBasic
187328318
CY2022Q3 alhc Weighted Average Number Of Shares Outstanding Net Of Restricted Shares Of Common Stock Diluted
WeightedAverageNumberOfSharesOutstandingNetOfRestrictedSharesOfCommonStockDiluted
182123363
CY2022Q3 alhc Weighted Average Number Of Shares Outstanding Net Of Restricted Shares Of Common Stock Basic
WeightedAverageNumberOfSharesOutstandingNetOfRestrictedSharesOfCommonStockBasic
182123363
alhc Weighted Average Number Of Shares Outstanding Net Of Restricted Shares Of Common Stock Diluted
WeightedAverageNumberOfSharesOutstandingNetOfRestrictedSharesOfCommonStockDiluted
185493345
alhc Weighted Average Number Of Shares Outstanding Net Of Restricted Shares Of Common Stock Basic
WeightedAverageNumberOfSharesOutstandingNetOfRestrictedSharesOfCommonStockBasic
185493345
alhc Weighted Average Number Of Shares Outstanding Net Of Restricted Shares Of Common Stock Basic
WeightedAverageNumberOfSharesOutstandingNetOfRestrictedSharesOfCommonStockBasic
180765300
alhc Weighted Average Number Of Shares Outstanding Net Of Restricted Shares Of Common Stock Diluted
WeightedAverageNumberOfSharesOutstandingNetOfRestrictedSharesOfCommonStockDiluted
180765300
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.19
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.19
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.22
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.22
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.54
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.54
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.51
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.51
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
26413563
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
19260153
CY2023Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
127058000
CY2022Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
2860000
us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2022 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2023Q3 us-gaap Government Contract Receivable
GovernmentContractReceivable
29367000
CY2022Q4 us-gaap Government Contract Receivable
GovernmentContractReceivable
33200000
CY2023Q3 alhc Pharmacy Rebates
PharmacyRebates
-72558000
CY2022Q4 alhc Pharmacy Rebates
PharmacyRebates
-54605000
CY2023Q3 us-gaap Other Receivables
OtherReceivables
3689000
CY2022Q4 us-gaap Other Receivables
OtherReceivables
5085000
CY2023Q3 us-gaap Accounts Receivable Gross
AccountsReceivableGross
105614000
CY2022Q4 us-gaap Accounts Receivable Gross
AccountsReceivableGross
92890000
CY2023Q3 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
91000
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0
CY2023Q3 us-gaap Accounts Receivable Net
AccountsReceivableNet
105523000
CY2022Q4 us-gaap Accounts Receivable Net
AccountsReceivableNet
92890000
CY2023Q3 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
40000
CY2022Q3 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
39000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
91000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
150000
CY2023Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
167267000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
142333000
CY2023Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
120105000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
105164000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
47162000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
37169000
CY2023Q3 us-gaap Depreciation
Depreciation
5534000
CY2022Q3 us-gaap Depreciation
Depreciation
4417000
us-gaap Depreciation
Depreciation
15609000
us-gaap Depreciation
Depreciation
12446000
CY2023Q3 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
361000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
7370000
CY2023Q3 us-gaap Goodwill Gross
GoodwillGross
34826000
CY2023Q3 us-gaap Goodwill Impaired Accumulated Impairment Loss
GoodwillImpairedAccumulatedImpairmentLoss
0
CY2023Q3 us-gaap Goodwill
Goodwill
34826000
CY2023Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
43543000
CY2023Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
-3437000
CY2023Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
40106000
CY2022Q4 us-gaap Goodwill Gross
GoodwillGross
34810000
CY2022Q4 us-gaap Goodwill Impaired Accumulated Impairment Loss
GoodwillImpairedAccumulatedImpairmentLoss
0
CY2022Q4 us-gaap Goodwill
Goodwill
34810000
CY2022Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
43527000
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
-3239000
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
40288000
CY2023Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
27000
CY2022Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
96000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
198000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
289000
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
28000
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
82000
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
60000
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
60000
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
60000
CY2023Q3 alhc Finite Lived Intangible Asset Expected Amortization Thereafter
FiniteLivedIntangibleAssetExpectedAmortizationThereafter
23000
CY2023Q3 alhc Estimated Amortization Expense Related To Intangible Assets
EstimatedAmortizationExpenseRelatedToIntangibleAssets
313000
CY2023Q3 us-gaap Goodwill And Intangible Asset Impairment
GoodwillAndIntangibleAssetImpairment
0
CY2022Q3 us-gaap Goodwill And Intangible Asset Impairment
GoodwillAndIntangibleAssetImpairment
0
us-gaap Goodwill And Intangible Asset Impairment
GoodwillAndIntangibleAssetImpairment
0
us-gaap Goodwill And Intangible Asset Impairment
GoodwillAndIntangibleAssetImpairment
0
us-gaap Schedule Of Liability For Unpaid Claims And Claims Adjustment Expense
ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense
<p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table is a detail of medical expenses payable as of </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">September 30, 2023 and December 31, 2022:</span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:66.76%;"></td> <td style="width:1.742%;"></td> <td style="width:1%;"></td> <td style="width:12.876999999999999%;"></td> <td style="width:1%;"></td> <td style="width:1.742%;"></td> <td style="width:1%;"></td> <td style="width:12.876999999999999%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">September 30,<br/>2023</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">December 31,<br/>2022</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Claims incurred but not paid</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">101,900</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">88,813</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Capitation payable and risk-sharing payable</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">45,128</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">50,818</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">56,407</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">30,504</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Medical expenses payable</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">203,435</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">170,135</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> </table>
CY2023Q3 us-gaap Liability For Unpaid Claims And Claims Adjustment Expense Incurred But Not Reported Ibnr Claims Amount
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount
101900000
CY2022Q4 us-gaap Liability For Unpaid Claims And Claims Adjustment Expense Incurred But Not Reported Ibnr Claims Amount
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount
88813000
CY2023Q3 alhc Liability For Claims And Claims Capitation Payable And Risk Sharing Payable
LiabilityForClaimsAndClaimsCapitationPayableAndRiskSharingPayable
45128000
CY2022Q4 alhc Liability For Claims And Claims Capitation Payable And Risk Sharing Payable
LiabilityForClaimsAndClaimsCapitationPayableAndRiskSharingPayable
50818000
CY2023Q3 alhc Liability For Claims And Claims Other Medical Expenses Payable
LiabilityForClaimsAndClaimsOtherMedicalExpensesPayable
56407000
CY2022Q4 alhc Liability For Claims And Claims Other Medical Expenses Payable
LiabilityForClaimsAndClaimsOtherMedicalExpensesPayable
30504000
CY2023Q3 us-gaap Liability For Claims And Claims Adjustment Expense
LiabilityForClaimsAndClaimsAdjustmentExpense
203435000
CY2022Q4 us-gaap Liability For Claims And Claims Adjustment Expense
LiabilityForClaimsAndClaimsAdjustmentExpense
170135000
alhc Remaining Claim Amounts Payment Period
RemainingClaimAmountsPaymentPeriod
P3Y
CY2022Q4 us-gaap Liability For Unpaid Claims And Claims Adjustment Expense Incurred But Not Reported Ibnr Claims Amount
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount
88813000
CY2021Q4 us-gaap Liability For Unpaid Claims And Claims Adjustment Expense Incurred But Not Reported Ibnr Claims Amount
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount
77073000
us-gaap Supplemental Information For Property Casualty Insurance Underwriters Current Year Claims And Claims Adjustment Expense
SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense
360372000
us-gaap Supplemental Information For Property Casualty Insurance Underwriters Current Year Claims And Claims Adjustment Expense
SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense
293036000
us-gaap Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense
SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
-10067000
us-gaap Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense
SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
-15757000
us-gaap Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
350305000
us-gaap Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
277279000
us-gaap Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Current Year1
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
266218000
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0
us-gaap Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Current Year1
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
212028000
us-gaap Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
71000000
us-gaap Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
56689000
us-gaap Payments For Losses And Loss Adjustment Expense
PaymentsForLossesAndLossAdjustmentExpense
337218000
us-gaap Payments For Losses And Loss Adjustment Expense
PaymentsForLossesAndLossAdjustmentExpense
268717000
CY2023Q3 us-gaap Liability For Unpaid Claims And Claims Adjustment Expense Incurred But Not Reported Ibnr Claims Amount
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount
101900000
CY2022Q3 us-gaap Liability For Unpaid Claims And Claims Adjustment Expense Incurred But Not Reported Ibnr Claims Amount
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount
85635000
CY2023Q3 alhc Liability For Claims And Claims Capitation Payable Risk Sharing Payable And Other
LiabilityForClaimsAndClaimsCapitationPayableRiskSharingPayableAndOther
101535000
CY2022Q3 alhc Liability For Claims And Claims Capitation Payable Risk Sharing Payable And Other
LiabilityForClaimsAndClaimsCapitationPayableRiskSharingPayableAndOther
85760000
CY2023Q3 us-gaap Liability For Claims And Claims Adjustment Expense
LiabilityForClaimsAndClaimsAdjustmentExpense
203435000
CY2022Q3 us-gaap Liability For Claims And Claims Adjustment Expense
LiabilityForClaimsAndClaimsAdjustmentExpense
171395000
CY2023Q3 alhc Claims Reserve Estimates Excluding Provision From Prior Year Claims And Claims Adjustment Expense
ClaimsReserveEstimatesExcludingProvisionFromPriorYearClaimsAndClaimsAdjustmentExpense
2929000
alhc Claims Reserve Estimates Excluding Provision From Prior Year Claims And Claims Adjustment Expense
ClaimsReserveEstimatesExcludingProvisionFromPriorYearClaimsAndClaimsAdjustmentExpense
5784000
CY2023Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
165000000
CY2022Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
165000000
CY2023Q3 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
3405000
CY2022Q4 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
4098000
CY2023Q3 us-gaap Long Term Debt
LongTermDebt
161595000
CY2022Q4 us-gaap Long Term Debt
LongTermDebt
160902000
CY2023Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
0
CY2022Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
0
CY2023Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
161595000
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
160902000
CY2023Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
1650000
CY2023Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
1650000
CY2023Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
161700000
CY2023Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
165000000
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2000
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
167000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
167000
CY2022Q4 alhc Operating Loss Carryforward Indefinite Life
OperatingLossCarryforwardIndefiniteLife
234742000
alhc Operating Loss Carryforwards Expiration Year
OperatingLossCarryforwardsExpirationYear
2033
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
10603493
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
16.90
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y3M18D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
3519000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0
CY2023Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
19369
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
18.41
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
10584124
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
16.9
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y18D
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
17595
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
17.94
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
10566529
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
16.9
CY2023Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y9M18D
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
294500
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
16.47
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
10272029
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
16.91
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y6M18D
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
4951671
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
17.43
CY2023Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y5M23D
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
0
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0
CY2023Q3 alhc Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue
0
alhc Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue
0
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
13569000
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
18687000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
51183000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
58833000
alhc Share Based Compensation Expense Unrecognized
ShareBasedCompensationExpenseUnrecognized
116294000
alhc Description Of Tangible Net Equity Requirement
DescriptionOfTangibleNetEquityRequirement
The required amount is the larger of: (1) $1,000; (2) 2% of the first $150,000 of annualized premium revenue, plus 1% of annualized premium revenue in excess of $150,000; or (3) 8% of the first $150,000 of annualized health care expenditures, except for those paid on a capitated or managed hospital payment basis, plus 4% of the annualized health care expenditures in excess of $150,000, except those paid on a capitated or managed hospital payment basis, plus 4% of annualized hospital expenditures paid on a managed hospital payment basis. We were in compliance with the TNE requirement as of September 30, 2023.
CY2023Q3 alhc Tangible Net Equity Required Amount
TangibleNetEquityRequiredAmount
1000000
alhc Annualized Premium Revenue Percentage
AnnualizedPremiumRevenuePercentage
0.02
CY2023Q3 us-gaap Tangible Capital Required For Capital Adequacy
TangibleCapitalRequiredForCapitalAdequacy
150000000
alhc Annualized Premium Revenue Excess Amount Percentage
AnnualizedPremiumRevenueExcessAmountPercentage
0.01
alhc Annualized Health Care Expenditures Percentage
AnnualizedHealthCareExpendituresPercentage
0.08
alhc Annualized Health Care Expenditures Excess Amount Percentage
AnnualizedHealthCareExpendituresExcessAmountPercentage
0.04
alhc Annualized Hospital Expenditure Paid Percentage
AnnualizedHospitalExpenditurePaidPercentage
0.04
us-gaap Loss Contingency Settlement Agreement Date
LossContingencySettlementAgreementDate
August 15, 2023
CY2023Q3 us-gaap Litigation Settlement Amount Awarded To Other Party
LitigationSettlementAmountAwardedToOtherParty
912500000
CY2023Q3 us-gaap Loss Contingency Accrual Carrying Value Current
LossContingencyAccrualCarryingValueCurrent
912500000
CY2023Q3 alhc Amounts Accrued For Legal Proceedings
AmountsAccruedForLegalProceedings
0
CY2022Q4 alhc Amounts Accrued For Legal Proceedings
AmountsAccruedForLegalProceedings
0

Files In Submission

Name View Source Status
0000950170-23-058207-index-headers.html Edgar Link pending
0000950170-23-058207-index.html Edgar Link pending
0000950170-23-058207.txt Edgar Link pending
0000950170-23-058207-xbrl.zip Edgar Link pending
alhc-20230930.htm Edgar Link pending
alhc-20230930.xsd Edgar Link pending
alhc-ex10_3.htm Edgar Link pending
alhc-ex31_1.htm Edgar Link pending
alhc-ex31_2.htm Edgar Link pending
alhc-ex32_1.htm Edgar Link pending
alhc-ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
alhc-20230930_cal.xml Edgar Link unprocessable
alhc-20230930_def.xml Edgar Link unprocessable
alhc-20230930_lab.xml Edgar Link unprocessable
alhc-20230930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
alhc-20230930_htm.xml Edgar Link completed
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending